Paper7909866
Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group.
Riethmüller G and 9 others. Lancet, 1994. Cited by 603 papers, by iCite.
Cite this record
ConductScience Library. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Papers, record 7909866. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7909866
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Monoclonal | Major topic |
| Antigens, Neoplasm | Major topic |
| Colorectal Neoplasms | Major topic |
| Chemotherapy, Adjuvant | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Neoplasm Metastasis | |
| Neoplasm Recurrence, Local | |
| Neoplasm Staging | |
| Patient Compliance | |
| Proportional Hazards Models | |
| Survival Analysis |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 7909862 | Minimal residual disease as the target for immunotherapy of cancer. | https://conductscience.org/library/papers/7909862 |
Source PubMed
Cited by120
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 603 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39595576 | High-Affinity Fully Human Anti-EpCAM Antibody with Biased IL-2 Exhibits Potent Antitumor Activity. | Biomolecules | 2024 | https://conductscience.org/library/papers/39595576 | PubMed |
| 38194912 | Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies. | Cancer Cell | 2024 | https://conductscience.org/library/papers/38194912 | PubMed |
| 38151631 | Unraveling the multifaceted role of EpCAM in colorectal cancer: an integrated review of its function and interplay with non-coding RNAs. | Med Oncol | 2023 | https://conductscience.org/library/papers/38151631 | PubMed |
| 38004421 | A Critical Analysis of the FDA's Omics-Driven Pharmacodynamic Biomarkers to Establish Biosimilarity. | Pharmaceuticals (Basel) | 2023 | https://conductscience.org/library/papers/38004421 | PubMed |
| 36369033 | Understanding the versatile roles and applications of EpCAM in cancers: from bench to bedside. | Exp Hematol Oncol | 2022 | https://conductscience.org/library/papers/36369033 | PubMed |
| 35986321 | Anti-cancer therapeutic strategies based on HGF/MET, EpCAM, and tumor-stromal cross talk. | Cancer Cell Int | 2022 | https://conductscience.org/library/papers/35986321 | PubMed |
| 35207472 | Identification, Culture and Targeting of Cancer Stem Cells. | Life (Basel) | 2022 | https://conductscience.org/library/papers/35207472 | PubMed |
| 35013776 | Preclinical evaluation of [99mTc]Tc-labeled anti-EpCAM nanobody for EpCAM receptor expression imaging by immuno-SPECT/CT. | Eur J Nucl Med Mol Imaging | 2022 | https://conductscience.org/library/papers/35013776 | PubMed |
| 33182510 | Recurrence Risk after Radical Colorectal Cancer Surgery-Less Than before, But How High Is It? | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/33182510 | PubMed |
| 32764280 | Epithelial Cell Adhesion Molecule: An Anchor to Isolate Clinically Relevant Circulating Tumor Cells. | Cells | 2020 | https://conductscience.org/library/papers/32764280 | PubMed |
| 32507912 | Expression and function of epithelial cell adhesion molecule EpCAM: where are we after 40 years? | Cancer Metastasis Rev | 2020 | https://conductscience.org/library/papers/32507912 | PubMed |
| 32046162 | Revisiting the Roles of Pro-Metastatic EpCAM in Cancer. | Biomolecules | 2020 | https://conductscience.org/library/papers/32046162 | PubMed |
| 31426611 | Cancer Stem Cells and Targeting Strategies. | Cells | 2019 | https://conductscience.org/library/papers/31426611 | PubMed |
| 29845054 | Targeting Colorectal Cancer Cell Lines Using Nanobodies; AgSK1as a Potential Target. | Iran J Biotechnol | 2017 | https://conductscience.org/library/papers/29845054 | PubMed |
| 29329202 | EpCAM Immunotherapy versus Specific Targeted Delivery of Drugs. | Cancers (Basel) | 2018 | https://conductscience.org/library/papers/29329202 | PubMed |
| 28531111 | Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives. | Int J Mol Sci | 2017 | https://conductscience.org/library/papers/28531111 | PubMed |
| 28301271 | Emerging trends and new developments in monoclonal antibodies: A scientometric analysis (1980-2016). | Hum Vaccin Immunother | 2017 | https://conductscience.org/library/papers/28301271 | PubMed |
| 27330354 | Reduction in membranous immunohistochemical staining for the intracellular domain of epithelial cell adhesion molecule correlates with poor patient outcome in primary colorectal adenocarcinoma. | Curr Oncol | 2016 | https://conductscience.org/library/papers/27330354 | PubMed |
| 26569228 | Exploring Different Strategies for Efficient Delivery of Colorectal Cancer Therapy. | Int J Mol Sci | 2015 | https://conductscience.org/library/papers/26569228 | PubMed |
| 26550566 | Production of monoclonal antibodies in plants for cancer immunotherapy. | Biomed Res Int | 2015 | https://conductscience.org/library/papers/26550566 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/7909866
GET https://conductscience.org/api/papers/v1/7909866/cited_by?page=2